Investigating the Functional Impact of CRBN Mutations on Response to IMiD/Celmod Agents in Myeloma
Yakinthi Chrisochoidou, Yann-Vai LeBihan, Salomon Morales, Shannon Martin et autres
Introduction Immunomodulatory drugs (IMiDs) have revolutionized the treatment of myeloma (MM), with lenalidomide (Len) and pomalidomide (Pom) approved and novel cereblon E3 ligase modulators (CELMoDs, e.g. iberdomide, Iber and mezigdomide, Mezi) in clinical trials. IMiDs and CELMoDs bind to cereblon (CRBN), which …
gb, us (code pays fourni par la source)